Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.48 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.45 |
| ▸ | RELA | Q04206 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4854918 | 0.82 | CHEK1 (0.48) | ACHECHEK1NPC1RAB9ATP53 | |
| SCHEMBL21939240 | 0.81 | ACHE (0.59) | ACHENPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL15222168 | 0.79 | IMPDH2 (0.51) | IMPDH2IMPDH1NPC1RAB9ATP53 | |
| SCHEMBL14600785 | 0.78 | S1PR1 (0.44) | ACHECHEK1NPC1RAB9ATP53 | |
| SCHEMBL21939273 | 0.78 | ACHE (0.56) | ACHENPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL31415554 | 0.78 | ACHE (0.59) | ACHENPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL5660762 | 0.78 | RAB9A (0.61) | NPC1RAB9ATP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL18031476 | 0.77 | KMT2A (0.54) | CHEK1NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL963294 | 0.77 | IMPDH2 (0.56) | CHEK1IMPDH2IMPDH1NPC1RAB9A | |
| SCHEMBL18031477 | 0.76 | MAPT (0.53) | CHEK1NPC1RAB9ATP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379553-B1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2013-06-26 | — | — | EP | disclosed |
| US-8349880-B2 | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2379553-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| EP-1485093-B1 | DI-ARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK SHARP & DOHME (US) | 2010-11-03 | — | — | EP | disclosed |
| WO-2010083141-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-22 | — | — | WO | disclosed |
| US-7592337-B2 | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1485093-A4 | DI-ARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050153986-A1 | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME LLC | 2005-07-14 | — | — | US | disclosed |
| EP-1485093-A1 | DI-ARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003077918-A1 | DI-ARYL SUBSTITUTED TETRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153986-A1 | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRIN2C | ACHE 2590/4885CHEK1 4413/4885IMPDH2 3920/4885 |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | APP, BACE1, APBA1 | ACHE 18/4885CHEK1 4705/4885IMPDH2 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.